Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Hum Mutat ; 33(7): 1075-86, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22374857

RESUMEN

Tens of thousands of lymphoblastoid cell lines (LCLs) have been established by the research community, providing nearly unlimited source material from samples of interest. LCLs are used to address questions in population genomics, mechanisms of disease, and pharmacogenomics. Thus, it is of fundamental importance to define the extent of chromosomal variation in LCLs. We measured variation in genotype and copy number in multiple LCLs derived from peripheral blood mononuclear cells (PBMCs) of single individuals as well as two comparison groups: (1) three types of differentiated cell lines (DCLs) and (2) triplicate HapMap samples. We then validated and extended our findings using data from a large study consisting of samples from blood or LCLs. We observed high concordances between genotypes and copy number estimates within all sample groups. While the genotypes of LCLs tended to faithfully reflect the genotypes of PBMCs, 13.7% (4 of 29) of immortalized cell lines harbored mosaic regions greater than 20 megabases, which were not present in PBMCs, DCLs, or HapMap replicate samples. We created a list of putative LCL-specific changes (affecting regions such as immunoglobulin loci) that is available as a community resource.


Asunto(s)
Variaciones en el Número de Copia de ADN/genética , Línea Celular , Células Cultivadas , Genotipo , Humanos , Polimorfismo de Nucleótido Simple/genética
2.
Lancet ; 375(9725): 1525-35, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20435227

RESUMEN

BACKGROUND: The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear. We aimed to undertake an integrated analysis of a complete human genome in a clinical context. METHODS: We assessed a patient with a family history of vascular disease and early sudden death. Clinical assessment included analysis of this patient's full genome sequence, risk prediction for coronary artery disease, screening for causes of sudden cardiac death, and genetic counselling. Genetic analysis included the development of novel methods for the integration of whole genome and clinical risk. Disease and risk analysis focused on prediction of genetic risk of variants associated with mendelian disease, recognised drug responses, and pathogenicity for novel variants. We queried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutations with known associations with disease and drug response. We estimated post-test probabilities of disease by applying likelihood ratios derived from integration of multiple common variants to age-appropriate and sex-appropriate pre-test probabilities. We also accounted for gene-environment interactions and conditionally dependent risks. FINDINGS: Analysis of 2.6 million single nucleotide polymorphisms and 752 copy number variations showed increased genetic risk for myocardial infarction, type 2 diabetes, and some cancers. We discovered rare variants in three genes that are clinically associated with sudden cardiac death-TMEM43, DSP, and MYBPC3. A variant in LPA was consistent with a family history of coronary artery disease. The patient had a heterozygous null mutation in CYP2C19 suggesting probable clopidogrel resistance, several variants associated with a positive response to lipid-lowering therapy, and variants in CYP4F2 and VKORC1 that suggest he might have a low initial dosing requirement for warfarin. Many variants of uncertain importance were reported. INTERPRETATION: Although challenges remain, our results suggest that whole-genome sequencing can yield useful and clinically relevant information for individual patients. FUNDING: National Institute of General Medical Sciences; National Heart, Lung And Blood Institute; National Human Genome Research Institute; Howard Hughes Medical Institute; National Library of Medicine, Lucile Packard Foundation for Children's Health; Hewlett Packard Foundation; Breetwor Family Foundation.


Asunto(s)
Predisposición Genética a la Enfermedad/genética , Pruebas Genéticas , Genoma Humano , Análisis de Secuencia de ADN , Enfermedades Vasculares/genética , Adulto , Hidrocarburo de Aril Hidroxilasas/genética , Proteínas Portadoras/genética , Citocromo P-450 CYP2C19 , Sistema Enzimático del Citocromo P-450/genética , Familia 4 del Citocromo P450 , Muerte Súbita Cardíaca , Desmoplaquinas/genética , Ambiente , Salud de la Familia , Asesoramiento Genético , Humanos , Lipoproteína(a)/genética , Masculino , Proteínas de la Membrana/genética , Oxigenasas de Función Mixta/genética , Mutación , Osteoartritis/genética , Linaje , Farmacogenética , Polimorfismo de Nucleótido Simple , Medición de Riesgo , Vitamina K Epóxido Reductasas
3.
Mol Genet Metab ; 104(1-2): 13-22, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21835664

RESUMEN

A December 2010 meeting, "Down Syndrome: National Conference on Patient Registries, Research Databases, and Biobanks," was jointly sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) in Bethesda, MD, and the Global Down Syndrome Foundation (GDSF)/Linda Crnic Institute for Down Syndrome based in Denver, CO. Approximately 70 attendees and organizers from various advocacy groups, federal agencies (Centers for Disease Control and Prevention, and various NIH Institutes, Centers, and Offices), members of industry, clinicians, and researchers from various academic institutions were greeted by Drs. Yvonne Maddox, Deputy Director of NICHD, and Edward McCabe, Executive Director of the Linda Crnic Institute for Down Syndrome. They charged the participants to focus on the separate issues of contact registries, research databases, and biobanks through both podium presentations and breakout session discussions. Among the breakout groups for each of the major sessions, participants were asked to generate responses to questions posed by the organizers concerning these three research resources as they related to Down syndrome and then to report back to the group at large with a summary of their discussions. This report represents a synthesis of the discussions and suggested approaches formulated by the group as a whole.


Asunto(s)
Bancos de Muestras Biológicas/estadística & datos numéricos , Investigación Biomédica/estadística & datos numéricos , Bases de Datos como Asunto/estadística & datos numéricos , Síndrome de Down/epidemiología , Sistema de Registros/estadística & datos numéricos , Humanos , Estados Unidos/epidemiología
4.
Drug Metab Rev ; 40(4): 539-51, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18949600

RESUMEN

The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB: http://www.pharmgkb.org) is devoted to disseminating primary data and knowledge in pharmacogenetics and pharmacogenomics. We are annotating the genes that are most important for drug response and present this information in the form of Very Important Pharmacogene (VIP) summaries, pathway diagrams, and curated literature. The PharmGKB currently contains information on over 500 drugs, 500 diseases, and 700 genes with genotyped variants. New features focus on capturing the phenotypic consequences of individual genetic variants. These features link variant genotypes to phenotypes, increase the breadth of pharmacogenomics literature curated, and visualize single-nucleotide polymorphisms on a gene's three-dimensional protein structure.


Asunto(s)
Variación Genética/genética , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Farmacogenética/métodos , Variación Genética/efectos de los fármacos , Humanos , Internet/normas , Farmacogenética/normas , Farmacogenética/tendencias , Estructura Secundaria de Proteína/efectos de los fármacos , Transducción de Señal/genética
7.
G3 (Bethesda) ; 3(7): 1143-9, 2013 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-23665875

RESUMEN

The Human Genetic Cell Repository sponsored by the National Institute of General Medical Sciences (NIGMS) contains more than 11,000 cell lines and DNA samples collected from numerous individuals. All of these cell lines and DNA samples are categorized into several collections representing a variety of disease states, chromosomal abnormalities, heritable diseases, distinct human populations, and apparently healthy individuals. Many of these cell lines have previously been studied with detailed conventional cytogenetic analyses, including G-banded karyotyping and fluorescence in situ hybridization. This work was conducted by investigators at submitting institutions and scientists at Coriell Institute for Medical Research, where the NIGMS Repository is hosted. Recently, approximately 900 cell lines, mostly chosen from the Chromosomal Aberrations and Heritable Diseases collections, have been further characterized in detail at the Coriell Institute using the Affymetrix Genome-Wide Human SNP Array 6.0 to detect copy number variations and copy number neutral loss of heterozygosity. A database containing detailed cytogenetic and genomic information for these cell lines has been constructed and is freely available through several sources, such as the NIGMS Repository website and the University of California at Santa Cruz Genome Browser. As additional cell lines are analyzed and subsequently added into it, the database will be maintained dynamically.


Asunto(s)
Línea Celular/citología , Trastornos de los Cromosomas/genética , Bases de Datos Genéticas , Análisis de Secuencia por Matrices de Oligonucleótidos , Línea Celular/metabolismo , Trastornos de los Cromosomas/patología , Análisis Citogenético , Genoma Humano , Humanos , Hibridación Fluorescente in Situ , Polimorfismo de Nucleótido Simple
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA